Vorapaxar expands antiplatelet options

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Background:

• Vorapaxar is a novel protease-activated receptor 1 (PAR-1) antagonist.
• It inhibits thrombin-induced platelet activation, targeting atherothrombosis.
• Clinical trials investigated its efficacy and safety in preventing ischemic events.

Purpose of the Study:

• To evaluate the efficacy and safety of vorapaxar in patients with acute coronary syndrome (ACS) and stable atherosclerosis.
• To determine if vorapaxar reduces ischemic events without an unacceptable increase in bleeding.

Main Methods:

• TRACER trial: Vorapaxar vs. placebo in 12,944 ACS patients on dual antiplatelet therapy.
• TRA 2P-TIMI 50 trial: Vorapaxar vs. placebo in 26,449 patients with a history of myocardial infarction, stroke, or peripheral arterial disease.
• Both trials assessed ischemic events and bleeding complications.

Main Results:

• In TRACER, vorapaxar did not significantly reduce ischemic events but significantly increased bleeding; follow-up was halted early.
• In TRA 2P-TIMI 50, vorapaxar significantly reduced ischemic events and significantly increased bleeding; stroke patient recruitment was stopped early.
• Subgroup analyses suggested potential benefit in patients with prior myocardial infarction but no history of stroke.

Conclusions:

• Vorapaxar's use in ACS is not justified due to increased bleeding risk without significant ischemic event reduction.
• Vorapaxar demonstrated a complex risk-benefit profile in stable atherosclerosis, with potential benefits in specific subgroups but increased bleeding concerns.